Does WRAPSODY Registry Data Change The Bull Case For Merit Medical Systems Stock (MMSI)?
- Merit Medical Systems reported third quarter 2026 sales of US$416.24 million and net income of US$42.31 million, raised full year revenue guidance slightly, and highlighted new real world WRAPSODY registry data that aligns with prior WAVE trial patency outcomes.
- The WRAPSODY device now has long term registry support across multiple geographies, while recent earnings and guidance updates provide investors with a clearer view of how this product suite fits into Merit Medical Systems’ broader mix of catheter based therapies and single use devices.
- This report now considers how Merit Medical Systems’ investment narrative may be influenced by stronger WRAPSODY evidence and raised guidance.
Merit Medical Systems Investment Narrative Recap
To own Merit Medical Systems, you need to believe the firm can keep lifting profitability while integrating new therapies like WRAPSODY into a broad catalog of single use devices. The analyst consensus Narrative on Simply Wall St leans on multi year efficiency work, product mix improvement and tuck in deals to support that view. Recent guidance was raised only slightly, so the near term catalyst still appears to be steady margin execution rather than a dramatic WRAPSODY revenue ramp.
The biggest near term risk remains WRAPSODY reimbursement and adoption not scaling as earlier hopes implied, especially with only about US$7 million of 2026 revenue referenced so far. Tariff expenses and pressure in China add extra friction. The latest quarter shows the business handling these headwinds, but they still limit how quickly earnings power can change.
The freshest operational data point for this story is the AVF cohort readout from the WRAP Global registry. WRAPSODY delivered 6 month target lesion primary patency of 92.7% and access circuit primary patency of 76.7%, closely in line with the WAVE pivotal trial. That matters because the WRAPSODY thesis rests on durable, real world performance and not just controlled trial data.
For catalysts, this registry result sits alongside expanding commercial availability in the United States, Europe, Canada and Brazil and supports Merit Medical Systems as it tries to earn more procedure share in dialysis access. It does not remove the reimbursement and adoption risk flagged in the analyst consensus Narrative on Simply Wall St, yet it gives physicians and payers more clinical evidence. Execution now is about converting this data advantage into actual device pull through without letting tariffs and softer China trends weigh too heavily on margins.
Merit Medical Systems' current analyst narrative points to revenues of US$1.9b and earnings of US$230.7 million by 2029, based on forecast top line growth of 6.2% a year and an earnings increase of about US$70.6 million from current earnings of US$160.1 million.
Uncover why Merit Medical Systems' fair value indicates a 20% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
Some of the most optimistic analysts frame WRAPSODY as a key upside swing factor for Merit Medical Systems, even before this new registry update. Before the news, the highest forecasts were already calling for around US$1.9b of revenue and US$271.1 million of earnings by 2029. That is a much more optimistic story than the consensus, and it shows how far opinions can stretch. Use this fresh data as a prompt to compare those different narratives for yourself, since both camps may revisit their numbers after the latest results.
Explore 2 other Merit Medical Systems fair value estimates, including one that suggests there could be as much as 34% upside from the current price!
Reach Your Own Conclusion
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Merit Medical Systems research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Merit Medical Systems. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Merit Medical Systems' overall financial health at a glance.
Looking for more investment ideas beyond Merit Medical Systems?
Once you have a view on Merit Medical Systems, it can help to line it up against a wider watchlist of opportunities using the Simply Wall St Screener. That way you see how its risk, balance sheet strength and income profile compare with other listed businesses chasing different outcomes.
- If you care most about resilient balance sheets and solid fundamentals, start by reviewing a list of solid balance sheet and fundamentals (23 results) that can help you stress test ideas against tougher conditions.
- Income focused investors can use a 6 dividend fortresses to spot companies that currently pair higher yields with an emphasis on stability.
- If you want to search for underappreciated opportunities, filter through a 19 high quality undiscovered gems and see which businesses have strong underlying metrics but lighter coverage.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com